Skip to main content
HCPCS Q2057 · Level II · Part B drug

Q2057: afamitresgene autoleucel (Tecelra), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q2057

Billing unit
PER THERAPEUTIC DOSE
Afamitresgene autoleucel
ASP payment limit
$813,967.375
October 2026; +0.0% vs July 2026
Practitioner MUE
1
MAI 2
OPPS status
SI G
APC 2067
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q2057 is the Level II code for Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose, billed per PER THERAPEUTIC DOSE. The Medicare Part B ASP payment limit for October 2026 is $813,967.375 per billing unit, up 0.0% from July 2026. The practitioner MUE allows up to 1 units per date of service (MAI 2), so a full 1-unit day is $813,967.38 at the current limit. Under OPPS it carries status indicator G in APC 2067. Q2057 is billed in units of PER THERAPEUTIC DOSE; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 1 NDC to it, sold as Tecelra by USWM, LLC. No current Billing and Coding Article lists Q2057, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q2057 at $813,967.375 per PER THERAPEUTIC DOSE for October 2026, derived from manufacturer average sales price plus 6%, compared with $813,967.375 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q2057
QuarterPayment limitPerCoinsurance
October 2026$813,967.375PER THERAPEUTIC DOSE20%
July 2026$813,967.375PER THERAPEUTIC DOSE—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to Q2057. Report the NDC in the claim's drug segment and bill the number of Q2057 units that equals the quantity administered divided by PER THERAPEUTIC DOSE; the last column gives units per full package.

NDCs that crosswalk to Q2057
NDCDrug nameLabelerPackage sizeBilling units / package
83205-0001-02TecelraUSWM, LLC1 × 11

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q2057. For practitioners the limit is 1 unit per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.

MUE values for Q2057 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services12 Date of Service Edit: PolicyCode Descriptor / CPT Instruction
Facility outpatient hospital12 Date of Service Edit: PolicyCode Descriptor / CPT Instruction

MUE for Q2057 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q2057 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q2057 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q2057 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q2057 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q2057 carries status indicator G and is assigned to APC 2067, with a published national unadjusted payment of $813,967.375. Status G marks pass-through drug payment, which is time-limited.

Common denials for Q2057 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q2057

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q2057

What does HCPCS code Q2057 describe?

Q2057 is defined by CMS as "Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose". Each billing unit represents PER THERAPEUTIC DOSE, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q2057 a CPT code?

No. Q2057 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as afamitresgene autoleucel (Tecelra); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q2057 reports the drug itself in per therapeutic dose units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q2057 in October 2026?

The ASP-based payment limit is $813,967.375 per PER THERAPEUTIC DOSE, with 20% beneficiary coinsurance. The July 2026 limit was $813,967.375. Commercial payers use their own fee schedules.

How many units of Q2057 can be billed per day?

The practitioner Medically Unlikely Edit is 1 units per date of service with adjudication indicator 2 (Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Code Descriptor / CPT Instruction" as the rationale.

Which NDCs map to Q2057?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Tecelra (USWM, LLC). For example NDC 83205-0001-02 (package size 1) equals 1 billing unit of Q2057.

Does Q2057 have NCCI bundling edits?

No active practitioner PTP pairs list Q2057 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.